These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2465100)

  • 1. Increased immunoreactivity of plasma after fibrinolytic activation in an anti-DD ELISA system. Role of soluble crosslinked fibrin polymers.
    Francis CW; Doughney K; Brenner B; Klingbiel K; Marder VJ
    Circulation; 1989 Mar; 79(3):666-73. PubMed ID: 2465100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma crosslinked fibrin polymers: quantitation based on tissue plasminogen activator conversion to D-dimer and measurement in normal and patients with acute thrombotic disorders.
    Kornberg A; Francis CW; Marder VJ
    Blood; 1992 Aug; 80(3):709-17. PubMed ID: 1386260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
    Eisenberg PR; Jaffe AS; Stump DC; Collen D; Bovill EG
    Circulation; 1990 Oct; 82(4):1159-68. PubMed ID: 2119264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific identification of fibrin polymers, fibrinogen degradation products, and crosslinked fibrin degradation products in plasma and serum with a new sensitive technique.
    Connaghan DG; Francis CW; Lane DA; Marder VJ
    Blood; 1985 Mar; 65(3):589-97. PubMed ID: 3971042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of soluble cross-linked fibrin in D dimer immunoreactivity of plasmic digests.
    Brenner B; Francis CW; Marder VJ
    J Lab Clin Med; 1989 Jun; 113(6):682-8. PubMed ID: 2732616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of antibody specificity in measuring cross-linked fibrin degradation products by ELISA.
    Eisenberg PR; Rylatt DB; Rusticali F; Ferrini D; Ottani F; Galvani M
    Blood Coagul Fibrinolysis; 1997 Mar; 8(2):105-13. PubMed ID: 9518041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction.
    Francis CW; Connaghan DG; Marder VJ
    Circulation; 1986 Nov; 74(5):1027-36. PubMed ID: 3533310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors.
    Weitz JI; Leslie B; Hudoba M
    Circulation; 1998 Feb; 97(6):544-52. PubMed ID: 9494024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
    Weitz JI; Leslie B; Ginsberg J
    J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivity of soluble fibrin assays with plasmic degradation products of fibrin and in patients receiving fibrinolytic therapy.
    McCarron BI; Marder VJ; Francis CW
    Thromb Haemost; 1999 Dec; 82(6):1722-9. PubMed ID: 10613661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombin-activable fibrinolysis inhibitor attenuates (DD)E-mediated stimulation of plasminogen activation by reducing the affinity of (DD)E for tissue plasminogen activator. A potential mechanism for enhancing the fibrin specificity of tissue plasminogen activator.
    Stewart RJ; Fredenburgh JC; Rischke JA; Bajzar L; Weitz JI
    J Biol Chem; 2000 Nov; 275(47):36612-20. PubMed ID: 10970891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis.
    Declerck PJ; Mombaerts P; Holvoet P; De Mol M; Collen D
    Thromb Haemost; 1987 Dec; 58(4):1024-9. PubMed ID: 3127914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A monoclonal antibody preventing binding of tissue-type plasminogen activator to fibrin: useful to monitor fibrinogen breakdown during t-PA infusion.
    Holvoet P; Lijnen HR; Collen D
    Blood; 1986 May; 67(5):1482-7. PubMed ID: 3083892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrin fragment D-dimer and fibrinogen B beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction.
    Lawler CM; Bovill EG; Stump DC; Collen DJ; Mann KG; Tracy RP
    Blood; 1990 Oct; 76(7):1341-8. PubMed ID: 2119827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in the fibrinolytic system components during acute myocardial infarction.
    Ioannidou-Papayannaki E; Lefkos N; Boudonas G; Efthimiadis A; Psirropoulos D; Vogas V; Papadopoulos I; Klonizakis I
    Acta Cardiol; 2000 Aug; 55(4):247-53. PubMed ID: 11041123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products.
    Suzuki A; Ebinuma H; Matsuo M; Miyazaki O; Yago H
    Thromb Res; 2007; 121(3):377-85. PubMed ID: 17561232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
    Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI
    Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble, cross-linked fibrin(ogen) hybrid oligomers do not stimulate t-PA conversion of plasminogen.
    Grøn B; Bennick A; Filion-Myklebust C; Matsueda GR; Nieuwenhuizen W; Brosstad F
    Thromb Res; 1992 May; 66(2-3):231-8. PubMed ID: 1412194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction.
    Francis CW; Connaghan DG; Scott WL; Marder VJ
    Circulation; 1987 Jun; 75(6):1170-7. PubMed ID: 3568326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies to crosslinked fibrin degradation products (XL-FDP). I. Characterization and preliminary evaluation in plasma.
    Gaffney PJ; Creighton LJ; Perry MJ; Callus M; Thorpe R; Spitz M
    Br J Haematol; 1988 Jan; 68(1):83-90. PubMed ID: 3345297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.